Cassava Sciences
From NEWSWIRE we learned that Cassava Sciences (SAVA), a clinical-stage biotechnology company focusing on Alzheimer’s disease, announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, has published results from the Company’s Phase 2a study; its drug PTI-125
This content is for paid subscribers.
Today’s Highlights
February 12, 2020
Cassava Sciences Has Good News from Alzheimer’s Disease Trial. See Also: Theravance Biopharma
Today’s Highlights February 12, 2020
